Health Archive » January, 2012

Health - January, 2012

248 articles

• Blue Shield Agrees To Cover Autism Therapy In Calif. Suit
• Chile Fines 2 Pharmacy Chains $38M For Price Fixing
• Micromet Investor Sues To Halt $1.2B Amgen Purchase
• Generic Cancer Drug MDL Tossed In Light Of Mensing
• Omnicare Faces OT Class Action By Technicians, Others
• Enzo, Roche Square Off Over Medical Testing Patent
• How To Lead A Practice Group
• Cadwalader Aids AngioDynamics In $372M Device Maker Buy
• Bayer Seeks to Block Pfizer's Bovine Drug With IP Suit
• Warner Chilcott Targeted Over Sales Reps' OT Pay
• Pfizer Wants Court To Pause Zoloft Birth Defects Suit
• Blue Cross Blasts Aetna's Antitrust Allegations
• AstraZeneca Sues Generics Maker Over Nexium Patents
• Coventry Rips Sanctions Bid In OSF Hospital Merger Fight
• FDA Accused Of Spying On Employee Scientists' Emails
• Ex-Symmetry Medical Workers Consent To Fraud Claims
• J&J, Merck Take Heat Over L'Oreal Sunscreen Patents
• Drug Co. Valeant Walks Away From Bid for Ista
• Kilpatrick Brings Finnegan IP Whiz To Silicon Valley
• Ex-McKesson Chair Asks High Court To Toss Guilty Verdict
• FTC Sues Omnicare To Block $441M PharMerica Merger
• Health Law Can Stand Even Without Mandate: White House
• Teva Unit Recalls Cancer Drug Treanda Over Glass Fragments
• Allergan Targets Hi-Tech Over IP For Glaucoma Generic
• Texas Denied Waiver On Health Reform Premium Rules
• FDA Reopens Comments On Drug Ad Rule In New Study's Wake
• Medtronic Hit With $10M Jury Verdict Over Catheter Patent
• Cooley Partner Takes GC Job At Jazz Pharmaceuticals
• Insurance Watchdog Investigating Lap-Band Centers: Aetna
• 5 Ways To Ramp Up Your Patent Portfolio
• Hospital Group Hid Whistleblower Suit: Investors
• EC Proceeds With Antitrust Probe Of French Drug Co.
• Jury Finds Varian Willfully Infringed Cancer Patent
• Affymetrix Suit Over Illumina Microarray IP Reopened
• AstraZeneca, Lupin Soothe Nexium Patent Fight
• Cordis Sues USPTO For Blocking Stent Re-Exam Subpoenas
• Pfizer Faces ERISA Stock-Drop Suit By Puerto Rico Workers
• Graceway's Ch. 11 Plan Hinges On Asset Sale
• Ex-CDC Official Gets 4 Years For Contract Bribes
• Celgene Snags Cancer Treatment Co. Avila For $350M
• Illumina Rebuffs $5.7B Roche Bid With Poison Pill
• Hospital Groups Clash Over Doc Request In Competition Battle
• Fed. Circ. Lifts Block On Generic Lovenox Sales
• A Health And Welfare Benefit Year In Review
• The Sentry That Guards Against The Tyranny Of Experts
• Ranbaxy Bows To Sweeping Penalties From US
• Sullivan Helps Amgen In $1.2B Micromet Buy
• Founder Of French Silicon Implant Co. Arrested Amid Scandal
• Forest Labs Bribed Study Authors To Boost Celexa: Suit
• Biotech Co. Affymetrix Pays $96M To End Investor Suit
• 4th Circ. Tosses Suit Over FDA-Approved Medtronic Device
• Ex-NY Sen. Espada, Son Deny False Statement Charges
• Cephalon Sues Mylan, Sandoz Again Over Generic Fentora
• State Farm Wins Provider Reimbursement Fight In 11th Circ.
• Celgene, Novartis Chastised Over Cancer Drug Claims
• CPSC Proposes Child-Resistant Packages for Decongestants
• Covidien Makes Deal With Watson To Allow Generic Exalgo
• Takeda Hid Gout, GERD Drug Interactions: Whistleblower
• Texas Abortion Law Opponents Seek 5th Circ. Rehearing
• Planned Parenthood Buys NY Headquarters For $35M
• Fed. Circ. Gives Roche 2nd Shot In Blood Test IP Fight
• Forest Labs Derivative Suit Belongs In Federal Court: Atty
• Biosimilars Law In Limbo
• Ex-HealthSouth CEO Gets 1 Year Dropped From Prison Time
• UK Probes Simplyhealth's $180M Dental Insurance Co. Buy
• Substantial Guidance For The FDA's 510(k) Program
• Roche Launches $5.7B Hostile Bid For Illumina
• Pfizer Triumphs Over Drinkmaker In Viagra Mark Dustup
• Novartis To Settle Sales Reps' OT Claims For $99M
• Canada, Novartis Issue Warning On Blood Pressure Drugs
• Health Group Of The Year: Weil Gotshal & Manges
• APP Settles Patent Row Over Generic Blood Thinner
• Cancer Agency Disliked Nonprofit, Barred Contract Bid: Suit
• EU Lawmakers Call For Tighter Controls On Breast Implants
• Bradley Arant Nabs Winston & Strawn Antitrust Atty
• Judge Cuts Conspiracy Claims Against Cigna, Others
• Ex-Canopy CEO Gets 15 Years For $93M Scheme
• Acura Settles Shareholder Claims Over Acurox For $1.5M
• Generics Cos. Fight Lovenox Injunction In Fed. Circ.
• Drug Co. Watson Grows Asian Presence With Ascent Buy
• CORRECTED: CRA Loses New Protest Over $230M Army Health Contract
• Broker-Dealers Elude BNY Mellon, Wells Fargo In MedCap MDL
• CR Bard, Others Face Onslaught Of Surgical Mesh Suits
• St. Jude Awarded $27M In Vascular Closure Device IP Fight
• Venable Lures 3 IP Experts From Patton Boggs
• Lilly Sues Accord Over Generic Lung Cancer Drug Alimta
• Abbott Sues Generic Maker Over Cholesterol Drug Patent
• Health Group Of The Year: Ropes & Gray
• FDA Delays Decision on Alexza Antipsychotic Treatment
• Sandoz Targeted Over Generic Cancer Drug Fusilev
• Kagan Recusal Arguments Nixed In High Court Health Fight
• FTC To Drop Antitrust Suit Over Lundbeck Heart Defect Drug
• FDA Panel Turns Down Columbia, Watson Preterm Birth Gel
• Meda Sues 2 Cos. Over Generic Nasal Spray Patent
• Wyeth, Cordis Stent Patents Are Invalid, Judge Says
• Fed. Circ. To Probe When Intervening Rights Kick In
• Health Group Of The Year: Covington & Burling
• Braintree, Buyers Settle Generic MiraLax Suit For $17M
• Dems Seek Probe Of Medical Device Cos.
• 11 Deaths Prompt EU Review Of Novartis Drug Gilenya
• The New Ease Of Terminating Section 501(c)(3) Status
• Expert Testimony OK In Miscarriage Drug Suit: Judge
• Genova Targets Kansas Lab Over Autism Test Patent Deal
• Merck Unit, Pamlab Sue Over Generic Metafolin
• Nurses Can Pursue Collective, Class Wage Actions: Judge
• Health Care Group Of The Year: Arnold & Porter
• Charges Against Stryker, Sales Staff Dropped For $15M
• FDA Seeks More Info On Bristol, AstraZeneca Diabetes Drug
• Siemens Devalued HearUSA Stock Ahead Of Takeover: Suit
• Merck Closes Out Canadian Vioxx Claims For Up To $36.5M
• 8 Insurers Settle Over Misleading Health Provider Info
• 4th Circ. Upholds GSK Win In Vaccine Contract Suit
• Pfizer Seeks To Merge 59 Zoloft Birth Defect Suits
• Foley Hoag Adds M&A, Securities Vet in Boston
• Another Look At W-2 Reporting Requirements
• J&J Settles Texas' Risperdal Suit For $158M
• Calif. Appeals Court Gives Hospital Wage Suit Another Shot
• Alnylam Claims Tekmira Infringed RNAi Tech Patents
• Covidien Recalls Chest Surgery Device After Patient Deaths
• Feds Push For 1st Circ. To Reopen FCA Suit Against Pfizer
• Latham Woos Pharma IP Pro From Wilson Sonsini
• Stiefel Can't Shake ERISA, Fraud Claims Over GSK Buy
• Health Group Of The Year: Akin Gump
• Stryker To Pay $15M To End False Marketing Case
• Baker Botts Lures McDermott M&A Pros To Calif. Digs
• Cadwalader Scores Top Dealmaker From Cahill Gordon
• Asian Buyout Firm Takes $100M Stake In DM Healthcare
• 2nd Circ. Quashes Savient Investor's Class Action
• IASIS Wins Sanctions Over Privileged Docs In FCA Case
• GSK Settles Bulk Of Avandia MDL Cases
• Judge Nixes Settlement In Rural/Metro Buyout Suit
• Feds Drop Charges Against Stryker Sales Manager
• Ex-Sanofi Researcher Cops To Trade Secrets Theft
• FDA Fines Red Cross $9.6M For Continued Missteps
• Supreme Court Lets 2 New Biz Owners Join Health Fight
• Fresenius Targets Nostrum's Generic PhosLo GelCaps
• The FDA Crackdown On Health Care Provider Ads
• Olympus Panel Clears KPMG, Ernst & Young In Fraud Probe
• Fed. Circ. Shuts Down Abbott Blood Test Patent Suit
• Wash. Gov., AGs Back Health Care Law In Supreme Court
• Price Uniformity Not Required For Cert.: 7th Circ.
• Burkle Bags Stake In Soho House For Reported $383M
• Merck Unit Sues To Block Teva's Generic Singulair
• Chemed Investors Sue Over Alleged Hospice Scam
• Brain Infection Reports Prompt Boxed Warning On Adcetris
• The 10 Worst Drug/Medical Device Decisions Of 2011
• Fed. Circ. Won't Let Bryan Cave Out Of AIA Patent Case
• McKesson's Bid To Revive Pill Dispenser IP Suit Nixed
• Lilly, 3rd-Party Payors Reach $4.5M Deal In Zyprexa Case
• Stryker Unit Settles Bone Staple Patent Suit
• Bankrupt Hospital Sues Over Malpractice Coverage
• Discovery Bid Heads To Canada In Lantheus Coverage Suit
• Inhibitex Investor Sues To Block $2.5B Bristol-Myers Deal
• CVS To Pay $5M To End FTC's Deceptive Drug Price Claims
• Atty Accused Of Defaming 3M Asks To Toss Case
• Quest Diagnostics Hit With $100M Sex Bias Suit
• PwC, Milliman To Pay $7M To Settle Hospital RICO Claims
• Insurer Tries To Dodge Defending Avastin Distributor
• ITC Staff Sides With Merck In NuvaRing Patent Battle
• Walgreen, Par Schemed To Overcharge For Generics: Suit
• Meritain Accuses Express Scripts Of Client Data Theft
• More Countries Raise Alarm Over Faulty Breast Implants
• Paul Weiss Reps Universal American In $228M APS Buy
• Perrigo Beats Reckitt Unit's Suit Over Generic Mucinex
• FDA Warns J&J Unit Over Insulin Pump Reporting Delays
• Medtronic Asks Fed. Circ. To Nix Edwards' $74M IP Award
• CHS Scrubs Hospital Buyout Amid FTC Review
• Novo Pays PE Firm $708M For Stake In Chr. Hansen
• FDA Advisers On Yaz Had Ties To Bayer: Ex-Agency Chief
• States Challenge Medicaid Expansion In Supreme Court
• 5th Circ. Lifts Injunction On Texas Fetal Sonogram Law
• Consumers Renew $29B Express Scripts, Medco Deal Fight
• FDA's Social Media Guidance Skirts Questions Of Liability
• CooperVision Hit With Investor Suit Over Lens Recall
• UCLA Still Silent On Data Breach Class Action
• Boehringer Blood Thinner Linked To Heart Attacks: Study
• SEC Adds New Suit To Ex-Wellcare CEO's Legal Woes
• Vytorin Derivative Suit Settlement Wins Initial Nod
• Judge Severs Charges Against Former Stryker Head
• Calif. County's Sherman Act Claim Nixed In Plasma MDL
• Streck Scores 2nd Fed. Circ. Win In Hematology IP Fight
• Weil Reps Sanofi On $125M Biotech Venture With VCs
• Partnering With The Feds For IP Enforcement: Part 1
• Carlton Fields Expands With Bankruptcy, Health Care Hires
• Shire Hits Sandoz With 2nd Suit Over Generic Intuniv
• Conceptus Loses Injunction Bid In Contraceptive IP Fight
• Linde Boosts European Home Care Business In $749M Buy
• Fed. Circ. Upholds Life Tech Injunction In Cell Patent Row
• Novartis Issues $120M Drug Recall, Plant Suspension
• Stryker Must Face Suit Over Joint Pain Pumps: Judge
• 'Not Whether, But How' To Improve Insurance Regulation
• Olympus Sues Ex-Chair, 2 Others Over Accounting Scandal
• Bryan Cave Helps Sigma-Aldrich In $350M Deal
• SK Capital, IBA To Form $229M Medical Imaging Venture
• DOJ Mounts High Court Defense Of Health Care Reform
• Drugmaker Valeant Losing Patience In $327M Hostile Bid
• Foreign Tobacco Cos. Can't Escape $50B Suit In Ontario
• Army Lets Health Care Cos. Revive Contract Bids
• Accenture Faces Fight Over $140M Medicaid Contract
• Perkins Coie's Chicago Office Adds 2 Finance Partners
• Rite Aid Overcharges Drug Discount Plan Members: Suit
• Aisling Capital, Others Inject $48M Into Roka Bioscience
• CVS Pharmacists Dispense Wage Suit Over Travel Pay
• Philips Slaps Rival With New Defibrillator Patent Suit
• Vioxx MDL Attys Shut Out Of $950M DOJ Settlement
• Knowledge Is Power In Failure-To-Warn Claims
• Ousted Olympus CEO Sues Over Dismissal
• Genzyme Wins Restrictions On Generic Arthritis Drug Price
• A Model For Olympus Shareholder Litigation
• Doc Linking Vaccines To Autism Sues Journal For Libel
• J&J To Pay $1B To Settle Risperdal Civil Claims: Report
• Kaye Scholer Nabs Ex-Frommer Lawrence IP Pro
• Schein Buys Oak Hill's Stake In Vet Supply Unit For $155M
• FTC Judge Orders ProMedica To Sell Off St. Luke's
• Takeda, Watson Sue Mylan Over Generic Actoplus Met XR
• The Latest On Off-Label Responses
• Actavis Pays $118M To Settle Drug Pricing Claims
• FDA Restricts Antibiotic Use In Food Animals
• Former St. Luke's Phlebotomist Sues Over OT Pay
• Ex-Cephalon GC Joins Morgan Lewis Litigation Group
• Pfizer Unit's Skelaxin Pay-For-Delay Deal Illegal: Suit
• FDA Orders Bard, Others To Study Surgical Mesh Implants
• Blue Shield Pays $2M To Settle Policy Rescission Action
• ITC Denies Sanctions Bid In NuvaRing Patent Row
• Pfizer Must Pay $45M In Menopause Drug Suits: Pa. Court
• Abbott Drops Patent Claims Over Teva's Generic Simcor
• DOJ's Emphasis On FCA Cases In 2011
• J&J Investors Renew Push For CEO Liability In Recalls
• Ex-McKesson Worker Files Pay, Seating Class Action
• Drilling Out The Competition: Not If The FTC Knows
• Reed Smith Reps Essex In $118M Biologics Deal
• Calif. Court Quashes AccentCare's Arbitration Mandate
• FDA Seeks To Streamline Medical Device Approvals
• 9th Circ. Puts Lid On Actimmune Marketing Action
• 7th Circ. Cites Anna Nicole In Nixing Debtors' Appeals
• Ex-Parkway Hospital CEO Cops To Bribing NY Lawmaker
• Jones Day Adds Ex-Health Care Fraud Chief
• US Seeks Prison Time For Ex-MediSys CEO In Bribery Case
• Spire Settles With Catheter Co. Over Recall, Deal Bungle
• AstraZeneca's Symbicort Inhaler Triggers Patent Suit
• Fed. Circ. Backs $5M Cordis Award In Stent Patent Suit
• DC Circ. Snuffs Out Suit Over FDA's Ear Candle Warnings
• Real Estate Strategies For Health Care Providers
• Varian Found To Infringe University's Radiation Patent
• Regeneron Strikes Deal With Genentech To Market Eylea
• Merck Canada Sues To Block Mylan's Generic Singulair
• Black & Decker, Others To Sweep Up RI Waste Site
• Judge Scraps First Bellwether Trial In Yaz MDL